nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP2B6—Tamoxifen—pancreatic cancer	0.0633	0.147	CbGbCtD
Mianserin—CYP2B6—Irinotecan—pancreatic cancer	0.0486	0.113	CbGbCtD
Mianserin—CYP1A2—Dacarbazine—pancreatic cancer	0.0467	0.108	CbGbCtD
Mianserin—CYP1A2—Tamoxifen—pancreatic cancer	0.0371	0.086	CbGbCtD
Mianserin—HRH2—gastric juice—pancreatic cancer	0.0318	0.441	CbGeAlD
Mianserin—CYP1A2—Erlotinib—pancreatic cancer	0.0316	0.0732	CbGbCtD
Mianserin—CYP2D6—Tamoxifen—pancreatic cancer	0.0306	0.0709	CbGbCtD
Mianserin—CYP1A2—Fluorouracil—pancreatic cancer	0.0274	0.0634	CbGbCtD
Mianserin—CYP2B6—Doxorubicin—pancreatic cancer	0.0266	0.0616	CbGbCtD
Mianserin—CYP2D6—Erlotinib—pancreatic cancer	0.026	0.0603	CbGbCtD
Mianserin—CYP3A4—Tamoxifen—pancreatic cancer	0.0195	0.0451	CbGbCtD
Mianserin—HTR7—enteric nervous system—pancreatic cancer	0.0172	0.238	CbGeAlD
Mianserin—CYP3A4—Erlotinib—pancreatic cancer	0.0165	0.0383	CbGbCtD
Mianserin—CYP3A4—Irinotecan—pancreatic cancer	0.0149	0.0346	CbGbCtD
Mianserin—CYP2D6—Doxorubicin—pancreatic cancer	0.0128	0.0297	CbGbCtD
Mianserin—CYP3A4—Docetaxel—pancreatic cancer	0.0109	0.0254	CbGbCtD
Mianserin—CYP3A4—Sunitinib—pancreatic cancer	0.0109	0.0252	CbGbCtD
Mianserin—HTR2A—enteric nervous system—pancreatic cancer	0.0107	0.149	CbGeAlD
Mianserin—CYP3A4—Doxorubicin—pancreatic cancer	0.00816	0.0189	CbGbCtD
Mianserin—HRH2—digestive system—pancreatic cancer	0.00194	0.0269	CbGeAlD
Mianserin—ADRA2A—islet of Langerhans—pancreatic cancer	0.00121	0.0167	CbGeAlD
Mianserin—SLC6A4—digestive system—pancreatic cancer	0.00116	0.0161	CbGeAlD
Mianserin—HTR2B—digestive system—pancreatic cancer	0.00115	0.016	CbGeAlD
Mianserin—ADRA2C—pancreas—pancreatic cancer	0.00106	0.0147	CbGeAlD
Mianserin—HTR7—digestive system—pancreatic cancer	0.000987	0.0137	CbGeAlD
Mianserin—ADRA2A—pancreas—pancreatic cancer	0.000848	0.0117	CbGeAlD
Mianserin—CYP1A2—digestive system—pancreatic cancer	0.000787	0.0109	CbGeAlD
Mianserin—CYP2B6—digestive system—pancreatic cancer	0.000755	0.0105	CbGeAlD
Mianserin—HRH1—digestive system—pancreatic cancer	0.000737	0.0102	CbGeAlD
Mianserin—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000721	0.00349	CcSEcCtD
Mianserin—Fatigue—Erlotinib—pancreatic cancer	0.00072	0.00348	CcSEcCtD
Mianserin—Constipation—Erlotinib—pancreatic cancer	0.000714	0.00345	CcSEcCtD
Mianserin—Shock—Sunitinib—pancreatic cancer	0.000711	0.00344	CcSEcCtD
Mianserin—Nervous system disorder—Sunitinib—pancreatic cancer	0.000709	0.00343	CcSEcCtD
Mianserin—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000707	0.00342	CcSEcCtD
Mianserin—Skin disorder—Sunitinib—pancreatic cancer	0.000702	0.0034	CcSEcCtD
Mianserin—Pancytopenia—Docetaxel—pancreatic cancer	0.000687	0.00333	CcSEcCtD
Mianserin—Neutropenia—Docetaxel—pancreatic cancer	0.000677	0.00327	CcSEcCtD
Mianserin—Anaemia—Irinotecan—pancreatic cancer	0.000674	0.00326	CcSEcCtD
Mianserin—Weight increased—Docetaxel—pancreatic cancer	0.000658	0.00319	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000658	0.00319	CcSEcCtD
Mianserin—Anaemia—Gemcitabine—pancreatic cancer	0.000657	0.00318	CcSEcCtD
Mianserin—Vertigo—Irinotecan—pancreatic cancer	0.000655	0.00317	CcSEcCtD
Mianserin—Syncope—Irinotecan—pancreatic cancer	0.000654	0.00317	CcSEcCtD
Mianserin—Leukopenia—Irinotecan—pancreatic cancer	0.000653	0.00316	CcSEcCtD
Mianserin—Paraesthesia—Sunitinib—pancreatic cancer	0.000649	0.00314	CcSEcCtD
Mianserin—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.000646	0.00313	CcSEcCtD
Mianserin—Anaemia—Fluorouracil—pancreatic cancer	0.000646	0.00312	CcSEcCtD
Mianserin—Loss of consciousness—Irinotecan—pancreatic cancer	0.000641	0.0031	CcSEcCtD
Mianserin—Leukopenia—Gemcitabine—pancreatic cancer	0.000636	0.00308	CcSEcCtD
Mianserin—Hypertension—Irinotecan—pancreatic cancer	0.00063	0.00305	CcSEcCtD
Mianserin—Jaundice—Docetaxel—pancreatic cancer	0.000629	0.00304	CcSEcCtD
Mianserin—Leukopenia—Fluorouracil—pancreatic cancer	0.000625	0.00303	CcSEcCtD
Mianserin—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000624	0.00302	CcSEcCtD
Mianserin—Fatigue—Sunitinib—pancreatic cancer	0.000623	0.00302	CcSEcCtD
Mianserin—Constipation—Sunitinib—pancreatic cancer	0.000618	0.00299	CcSEcCtD
Mianserin—HTR2A—digestive system—pancreatic cancer	0.000616	0.00853	CbGeAlD
Mianserin—Hypertension—Gemcitabine—pancreatic cancer	0.000613	0.00297	CcSEcCtD
Mianserin—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.00061	0.00295	CcSEcCtD
Mianserin—Asthenia—Tamoxifen—pancreatic cancer	0.000605	0.00293	CcSEcCtD
Mianserin—Convulsion—Fluorouracil—pancreatic cancer	0.000605	0.00293	CcSEcCtD
Mianserin—Arthralgia—Gemcitabine—pancreatic cancer	0.000605	0.00293	CcSEcCtD
Mianserin—Myalgia—Gemcitabine—pancreatic cancer	0.000605	0.00293	CcSEcCtD
Mianserin—Agranulocytosis—Docetaxel—pancreatic cancer	0.000602	0.00291	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000601	0.00291	CcSEcCtD
Mianserin—Confusional state—Irinotecan—pancreatic cancer	0.0006	0.0029	CcSEcCtD
Mianserin—Asthenia—Erlotinib—pancreatic cancer	0.000599	0.0029	CcSEcCtD
Mianserin—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.000598	0.00289	CcSEcCtD
Mianserin—Pruritus—Tamoxifen—pancreatic cancer	0.000597	0.00289	CcSEcCtD
Mianserin—Oedema—Irinotecan—pancreatic cancer	0.000595	0.00288	CcSEcCtD
Mianserin—Myalgia—Fluorouracil—pancreatic cancer	0.000595	0.00288	CcSEcCtD
Mianserin—Pruritus—Erlotinib—pancreatic cancer	0.000591	0.00286	CcSEcCtD
Mianserin—Shock—Irinotecan—pancreatic cancer	0.000586	0.00283	CcSEcCtD
Mianserin—Nervous system disorder—Irinotecan—pancreatic cancer	0.000584	0.00283	CcSEcCtD
Mianserin—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000583	0.00282	CcSEcCtD
Mianserin—Oedema—Gemcitabine—pancreatic cancer	0.00058	0.00281	CcSEcCtD
Mianserin—Hepatitis—Docetaxel—pancreatic cancer	0.000579	0.0028	CcSEcCtD
Mianserin—Cardiac failure—Epirubicin—pancreatic cancer	0.000579	0.0028	CcSEcCtD
Mianserin—Lethargy—Epirubicin—pancreatic cancer	0.000576	0.00279	CcSEcCtD
Mianserin—Confusional state—Fluorouracil—pancreatic cancer	0.000575	0.00278	CcSEcCtD
Mianserin—Oedema—Fluorouracil—pancreatic cancer	0.00057	0.00276	CcSEcCtD
Mianserin—CYP3A4—digestive system—pancreatic cancer	0.00057	0.0079	CbGeAlD
Mianserin—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000569	0.00275	CcSEcCtD
Mianserin—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000569	0.00275	CcSEcCtD
Mianserin—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000568	0.00275	CcSEcCtD
Mianserin—Diplopia—Epirubicin—pancreatic cancer	0.000565	0.00273	CcSEcCtD
Mianserin—Skin disorder—Gemcitabine—pancreatic cancer	0.000563	0.00273	CcSEcCtD
Mianserin—CYP2D6—digestive system—pancreatic cancer	0.000561	0.00777	CbGeAlD
Mianserin—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000559	0.00271	CcSEcCtD
Mianserin—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000558	0.0027	CcSEcCtD
Mianserin—Dizziness—Tamoxifen—pancreatic cancer	0.000558	0.0027	CcSEcCtD
Mianserin—Tachycardia—Fluorouracil—pancreatic cancer	0.000556	0.00269	CcSEcCtD
Mianserin—Hypotension—Irinotecan—pancreatic cancer	0.000556	0.00269	CcSEcCtD
Mianserin—Dizziness—Erlotinib—pancreatic cancer	0.000552	0.00267	CcSEcCtD
Mianserin—Hypotension—Gemcitabine—pancreatic cancer	0.000542	0.00262	CcSEcCtD
Mianserin—Eye disorder—Docetaxel—pancreatic cancer	0.000541	0.00262	CcSEcCtD
Mianserin—Cardiac disorder—Docetaxel—pancreatic cancer	0.000537	0.0026	CcSEcCtD
Mianserin—Cardiac arrest—Epirubicin—pancreatic cancer	0.000537	0.0026	CcSEcCtD
Mianserin—Cardiac failure—Doxorubicin—pancreatic cancer	0.000535	0.00259	CcSEcCtD
Mianserin—Paraesthesia—Irinotecan—pancreatic cancer	0.000534	0.00259	CcSEcCtD
Mianserin—Lethargy—Doxorubicin—pancreatic cancer	0.000533	0.00258	CcSEcCtD
Mianserin—Hypotension—Fluorouracil—pancreatic cancer	0.000533	0.00258	CcSEcCtD
Mianserin—Rash—Tamoxifen—pancreatic cancer	0.000532	0.00257	CcSEcCtD
Mianserin—Dermatitis—Tamoxifen—pancreatic cancer	0.000531	0.00257	CcSEcCtD
Mianserin—Somnolence—Irinotecan—pancreatic cancer	0.000529	0.00256	CcSEcCtD
Mianserin—Headache—Tamoxifen—pancreatic cancer	0.000529	0.00256	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000528	0.00256	CcSEcCtD
Mianserin—Rash—Erlotinib—pancreatic cancer	0.000526	0.00255	CcSEcCtD
Mianserin—Dermatitis—Erlotinib—pancreatic cancer	0.000526	0.00255	CcSEcCtD
Mianserin—Angiopathy—Docetaxel—pancreatic cancer	0.000525	0.00254	CcSEcCtD
Mianserin—Headache—Erlotinib—pancreatic cancer	0.000523	0.00253	CcSEcCtD
Mianserin—Diplopia—Doxorubicin—pancreatic cancer	0.000522	0.00253	CcSEcCtD
Mianserin—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000522	0.00253	CcSEcCtD
Mianserin—Paraesthesia—Gemcitabine—pancreatic cancer	0.000521	0.00252	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000519	0.00251	CcSEcCtD
Mianserin—Asthenia—Sunitinib—pancreatic cancer	0.000518	0.00251	CcSEcCtD
Mianserin—Somnolence—Gemcitabine—pancreatic cancer	0.000515	0.00249	CcSEcCtD
Mianserin—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000514	0.00249	CcSEcCtD
Mianserin—Fatigue—Irinotecan—pancreatic cancer	0.000513	0.00248	CcSEcCtD
Mianserin—Paraesthesia—Fluorouracil—pancreatic cancer	0.000512	0.00248	CcSEcCtD
Mianserin—Pruritus—Sunitinib—pancreatic cancer	0.000511	0.00247	CcSEcCtD
Mianserin—Breast disorder—Epirubicin—pancreatic cancer	0.00051	0.00247	CcSEcCtD
Mianserin—Constipation—Irinotecan—pancreatic cancer	0.000509	0.00246	CcSEcCtD
Mianserin—Mental disorder—Docetaxel—pancreatic cancer	0.000507	0.00246	CcSEcCtD
Mianserin—Somnolence—Fluorouracil—pancreatic cancer	0.000507	0.00245	CcSEcCtD
Mianserin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000501	0.00242	CcSEcCtD
Mianserin—Fatigue—Gemcitabine—pancreatic cancer	0.0005	0.00242	CcSEcCtD
Mianserin—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000497	0.0024	CcSEcCtD
Mianserin—Constipation—Gemcitabine—pancreatic cancer	0.000496	0.0024	CcSEcCtD
Mianserin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000492	0.00238	CcSEcCtD
Mianserin—Feeling abnormal—Irinotecan—pancreatic cancer	0.00049	0.00237	CcSEcCtD
Mianserin—Dizziness—Sunitinib—pancreatic cancer	0.000478	0.00231	CcSEcCtD
Mianserin—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000478	0.00231	CcSEcCtD
Mianserin—Breast disorder—Doxorubicin—pancreatic cancer	0.000472	0.00229	CcSEcCtD
Mianserin—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00047	0.00227	CcSEcCtD
Mianserin—Anaemia—Docetaxel—pancreatic cancer	0.000466	0.00226	CcSEcCtD
Mianserin—Pancytopenia—Epirubicin—pancreatic cancer	0.000463	0.00224	CcSEcCtD
Mianserin—Neutropenia—Epirubicin—pancreatic cancer	0.000456	0.00221	CcSEcCtD
Mianserin—Rash—Sunitinib—pancreatic cancer	0.000456	0.00221	CcSEcCtD
Mianserin—Dermatitis—Sunitinib—pancreatic cancer	0.000455	0.0022	CcSEcCtD
Mianserin—Headache—Sunitinib—pancreatic cancer	0.000453	0.00219	CcSEcCtD
Mianserin—Syncope—Docetaxel—pancreatic cancer	0.000452	0.00219	CcSEcCtD
Mianserin—Leukopenia—Docetaxel—pancreatic cancer	0.000451	0.00218	CcSEcCtD
Mianserin—Weight increased—Epirubicin—pancreatic cancer	0.000444	0.00215	CcSEcCtD
Mianserin—Loss of consciousness—Docetaxel—pancreatic cancer	0.000443	0.00214	CcSEcCtD
Mianserin—Convulsion—Docetaxel—pancreatic cancer	0.000437	0.00211	CcSEcCtD
Mianserin—Hypertension—Docetaxel—pancreatic cancer	0.000435	0.00211	CcSEcCtD
Mianserin—Drowsiness—Epirubicin—pancreatic cancer	0.000435	0.00211	CcSEcCtD
Mianserin—Arthralgia—Docetaxel—pancreatic cancer	0.000429	0.00208	CcSEcCtD
Mianserin—Myalgia—Docetaxel—pancreatic cancer	0.000429	0.00208	CcSEcCtD
Mianserin—Pancytopenia—Doxorubicin—pancreatic cancer	0.000429	0.00208	CcSEcCtD
Mianserin—Asthenia—Irinotecan—pancreatic cancer	0.000427	0.00207	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000426	0.00206	CcSEcCtD
Mianserin—Jaundice—Epirubicin—pancreatic cancer	0.000424	0.00205	CcSEcCtD
Mianserin—Neutropenia—Doxorubicin—pancreatic cancer	0.000422	0.00204	CcSEcCtD
Mianserin—Dry mouth—Docetaxel—pancreatic cancer	0.00042	0.00203	CcSEcCtD
Mianserin—Asthenia—Gemcitabine—pancreatic cancer	0.000416	0.00201	CcSEcCtD
Mianserin—Confusional state—Docetaxel—pancreatic cancer	0.000415	0.00201	CcSEcCtD
Mianserin—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000412	0.00199	CcSEcCtD
Mianserin—Oedema—Docetaxel—pancreatic cancer	0.000411	0.00199	CcSEcCtD
Mianserin—Weight increased—Doxorubicin—pancreatic cancer	0.000411	0.00199	CcSEcCtD
Mianserin—Pruritus—Gemcitabine—pancreatic cancer	0.00041	0.00199	CcSEcCtD
Mianserin—Agranulocytosis—Epirubicin—pancreatic cancer	0.000406	0.00197	CcSEcCtD
Mianserin—Shock—Docetaxel—pancreatic cancer	0.000405	0.00196	CcSEcCtD
Mianserin—Nervous system disorder—Docetaxel—pancreatic cancer	0.000403	0.00195	CcSEcCtD
Mianserin—Pruritus—Fluorouracil—pancreatic cancer	0.000403	0.00195	CcSEcCtD
Mianserin—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000403	0.00195	CcSEcCtD
Mianserin—Drowsiness—Doxorubicin—pancreatic cancer	0.000403	0.00195	CcSEcCtD
Mianserin—Tachycardia—Docetaxel—pancreatic cancer	0.000402	0.00194	CcSEcCtD
Mianserin—Skin disorder—Docetaxel—pancreatic cancer	0.0004	0.00193	CcSEcCtD
Mianserin—Bradycardia—Epirubicin—pancreatic cancer	0.000398	0.00192	CcSEcCtD
Mianserin—Dizziness—Irinotecan—pancreatic cancer	0.000394	0.00191	CcSEcCtD
Mianserin—Jaundice—Doxorubicin—pancreatic cancer	0.000392	0.0019	CcSEcCtD
Mianserin—Hepatitis—Epirubicin—pancreatic cancer	0.000391	0.00189	CcSEcCtD
Mianserin—Hypotension—Docetaxel—pancreatic cancer	0.000384	0.00186	CcSEcCtD
Mianserin—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000384	0.00186	CcSEcCtD
Mianserin—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000381	0.00184	CcSEcCtD
Mianserin—Dizziness—Fluorouracil—pancreatic cancer	0.000377	0.00182	CcSEcCtD
Mianserin—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000376	0.00182	CcSEcCtD
Mianserin—Rash—Irinotecan—pancreatic cancer	0.000375	0.00182	CcSEcCtD
Mianserin—Dermatitis—Irinotecan—pancreatic cancer	0.000375	0.00181	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000375	0.00181	CcSEcCtD
Mianserin—Headache—Irinotecan—pancreatic cancer	0.000373	0.0018	CcSEcCtD
Mianserin—Paraesthesia—Docetaxel—pancreatic cancer	0.000369	0.00179	CcSEcCtD
Mianserin—Bradycardia—Doxorubicin—pancreatic cancer	0.000368	0.00178	CcSEcCtD
Mianserin—Somnolence—Docetaxel—pancreatic cancer	0.000366	0.00177	CcSEcCtD
Mianserin—Rash—Gemcitabine—pancreatic cancer	0.000366	0.00177	CcSEcCtD
Mianserin—Dermatitis—Gemcitabine—pancreatic cancer	0.000365	0.00177	CcSEcCtD
Mianserin—Eye disorder—Epirubicin—pancreatic cancer	0.000365	0.00177	CcSEcCtD
Mianserin—Tinnitus—Epirubicin—pancreatic cancer	0.000364	0.00176	CcSEcCtD
Mianserin—Headache—Gemcitabine—pancreatic cancer	0.000363	0.00176	CcSEcCtD
Mianserin—Cardiac disorder—Epirubicin—pancreatic cancer	0.000363	0.00175	CcSEcCtD
Mianserin—Hepatitis—Doxorubicin—pancreatic cancer	0.000361	0.00175	CcSEcCtD
Mianserin—Rash—Fluorouracil—pancreatic cancer	0.000359	0.00174	CcSEcCtD
Mianserin—Dermatitis—Fluorouracil—pancreatic cancer	0.000359	0.00174	CcSEcCtD
Mianserin—Headache—Fluorouracil—pancreatic cancer	0.000357	0.00173	CcSEcCtD
Mianserin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000355	0.00172	CcSEcCtD
Mianserin—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000355	0.00172	CcSEcCtD
Mianserin—Fatigue—Docetaxel—pancreatic cancer	0.000355	0.00172	CcSEcCtD
Mianserin—Angiopathy—Epirubicin—pancreatic cancer	0.000354	0.00172	CcSEcCtD
Mianserin—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000352	0.0017	CcSEcCtD
Mianserin—Constipation—Docetaxel—pancreatic cancer	0.000352	0.0017	CcSEcCtD
Mianserin—Mental disorder—Epirubicin—pancreatic cancer	0.000342	0.00166	CcSEcCtD
Mianserin—Feeling abnormal—Docetaxel—pancreatic cancer	0.000339	0.00164	CcSEcCtD
Mianserin—Eye disorder—Doxorubicin—pancreatic cancer	0.000338	0.00163	CcSEcCtD
Mianserin—Tinnitus—Doxorubicin—pancreatic cancer	0.000337	0.00163	CcSEcCtD
Mianserin—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000335	0.00162	CcSEcCtD
Mianserin—Angiopathy—Doxorubicin—pancreatic cancer	0.000328	0.00159	CcSEcCtD
Mianserin—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000326	0.00158	CcSEcCtD
Mianserin—Mental disorder—Doxorubicin—pancreatic cancer	0.000317	0.00153	CcSEcCtD
Mianserin—Anaemia—Epirubicin—pancreatic cancer	0.000314	0.00152	CcSEcCtD
Mianserin—Agitation—Epirubicin—pancreatic cancer	0.000312	0.00151	CcSEcCtD
Mianserin—Vertigo—Epirubicin—pancreatic cancer	0.000306	0.00148	CcSEcCtD
Mianserin—Syncope—Epirubicin—pancreatic cancer	0.000305	0.00148	CcSEcCtD
Mianserin—Leukopenia—Epirubicin—pancreatic cancer	0.000304	0.00147	CcSEcCtD
Mianserin—Loss of consciousness—Epirubicin—pancreatic cancer	0.000299	0.00145	CcSEcCtD
Mianserin—Asthenia—Docetaxel—pancreatic cancer	0.000295	0.00143	CcSEcCtD
Mianserin—Convulsion—Epirubicin—pancreatic cancer	0.000295	0.00143	CcSEcCtD
Mianserin—Hypertension—Epirubicin—pancreatic cancer	0.000294	0.00142	CcSEcCtD
Mianserin—Pruritus—Docetaxel—pancreatic cancer	0.000291	0.00141	CcSEcCtD
Mianserin—Anaemia—Doxorubicin—pancreatic cancer	0.000291	0.00141	CcSEcCtD
Mianserin—Arthralgia—Epirubicin—pancreatic cancer	0.000289	0.0014	CcSEcCtD
Mianserin—Myalgia—Epirubicin—pancreatic cancer	0.000289	0.0014	CcSEcCtD
Mianserin—Agitation—Doxorubicin—pancreatic cancer	0.000289	0.0014	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000288	0.00139	CcSEcCtD
Mianserin—Dry mouth—Epirubicin—pancreatic cancer	0.000283	0.00137	CcSEcCtD
Mianserin—Vertigo—Doxorubicin—pancreatic cancer	0.000283	0.00137	CcSEcCtD
Mianserin—Syncope—Doxorubicin—pancreatic cancer	0.000282	0.00137	CcSEcCtD
Mianserin—Leukopenia—Doxorubicin—pancreatic cancer	0.000282	0.00136	CcSEcCtD
Mianserin—Confusional state—Epirubicin—pancreatic cancer	0.00028	0.00135	CcSEcCtD
Mianserin—Oedema—Epirubicin—pancreatic cancer	0.000278	0.00134	CcSEcCtD
Mianserin—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000277	0.00134	CcSEcCtD
Mianserin—Shock—Epirubicin—pancreatic cancer	0.000273	0.00132	CcSEcCtD
Mianserin—Convulsion—Doxorubicin—pancreatic cancer	0.000273	0.00132	CcSEcCtD
Mianserin—Nervous system disorder—Epirubicin—pancreatic cancer	0.000272	0.00132	CcSEcCtD
Mianserin—Dizziness—Docetaxel—pancreatic cancer	0.000272	0.00132	CcSEcCtD
Mianserin—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000272	0.00132	CcSEcCtD
Mianserin—Hypertension—Doxorubicin—pancreatic cancer	0.000272	0.00131	CcSEcCtD
Mianserin—Tachycardia—Epirubicin—pancreatic cancer	0.000271	0.00131	CcSEcCtD
Mianserin—Skin disorder—Epirubicin—pancreatic cancer	0.00027	0.0013	CcSEcCtD
Mianserin—Arthralgia—Doxorubicin—pancreatic cancer	0.000268	0.0013	CcSEcCtD
Mianserin—Myalgia—Doxorubicin—pancreatic cancer	0.000268	0.0013	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000266	0.00129	CcSEcCtD
Mianserin—Dry mouth—Doxorubicin—pancreatic cancer	0.000262	0.00127	CcSEcCtD
Mianserin—Rash—Docetaxel—pancreatic cancer	0.000259	0.00126	CcSEcCtD
Mianserin—Hypotension—Epirubicin—pancreatic cancer	0.000259	0.00126	CcSEcCtD
Mianserin—Dermatitis—Docetaxel—pancreatic cancer	0.000259	0.00125	CcSEcCtD
Mianserin—Confusional state—Doxorubicin—pancreatic cancer	0.000259	0.00125	CcSEcCtD
Mianserin—Headache—Docetaxel—pancreatic cancer	0.000258	0.00125	CcSEcCtD
Mianserin—Oedema—Doxorubicin—pancreatic cancer	0.000257	0.00124	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000253	0.00122	CcSEcCtD
Mianserin—Shock—Doxorubicin—pancreatic cancer	0.000253	0.00122	CcSEcCtD
Mianserin—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000252	0.00122	CcSEcCtD
Mianserin—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000251	0.00122	CcSEcCtD
Mianserin—Tachycardia—Doxorubicin—pancreatic cancer	0.000251	0.00121	CcSEcCtD
Mianserin—Skin disorder—Doxorubicin—pancreatic cancer	0.000249	0.00121	CcSEcCtD
Mianserin—Paraesthesia—Epirubicin—pancreatic cancer	0.000249	0.00121	CcSEcCtD
Mianserin—Somnolence—Epirubicin—pancreatic cancer	0.000247	0.00119	CcSEcCtD
Mianserin—Hypotension—Doxorubicin—pancreatic cancer	0.00024	0.00116	CcSEcCtD
Mianserin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.00024	0.00116	CcSEcCtD
Mianserin—Fatigue—Epirubicin—pancreatic cancer	0.000239	0.00116	CcSEcCtD
Mianserin—Constipation—Epirubicin—pancreatic cancer	0.000237	0.00115	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000234	0.00113	CcSEcCtD
Mianserin—Paraesthesia—Doxorubicin—pancreatic cancer	0.000231	0.00112	CcSEcCtD
Mianserin—Feeling abnormal—Epirubicin—pancreatic cancer	0.000229	0.00111	CcSEcCtD
Mianserin—Somnolence—Doxorubicin—pancreatic cancer	0.000228	0.0011	CcSEcCtD
Mianserin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000222	0.00107	CcSEcCtD
Mianserin—Fatigue—Doxorubicin—pancreatic cancer	0.000221	0.00107	CcSEcCtD
Mianserin—Constipation—Doxorubicin—pancreatic cancer	0.00022	0.00106	CcSEcCtD
Mianserin—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000212	0.00102	CcSEcCtD
Mianserin—Asthenia—Epirubicin—pancreatic cancer	0.000199	0.000964	CcSEcCtD
Mianserin—Pruritus—Epirubicin—pancreatic cancer	0.000196	0.00095	CcSEcCtD
Mianserin—Asthenia—Doxorubicin—pancreatic cancer	0.000184	0.000892	CcSEcCtD
Mianserin—Dizziness—Epirubicin—pancreatic cancer	0.000184	0.000888	CcSEcCtD
Mianserin—Pruritus—Doxorubicin—pancreatic cancer	0.000182	0.000879	CcSEcCtD
Mianserin—Rash—Epirubicin—pancreatic cancer	0.000175	0.000847	CcSEcCtD
Mianserin—Dermatitis—Epirubicin—pancreatic cancer	0.000175	0.000846	CcSEcCtD
Mianserin—Headache—Epirubicin—pancreatic cancer	0.000174	0.000842	CcSEcCtD
Mianserin—Dizziness—Doxorubicin—pancreatic cancer	0.00017	0.000822	CcSEcCtD
Mianserin—Rash—Doxorubicin—pancreatic cancer	0.000162	0.000784	CcSEcCtD
Mianserin—Dermatitis—Doxorubicin—pancreatic cancer	0.000162	0.000783	CcSEcCtD
Mianserin—Headache—Doxorubicin—pancreatic cancer	0.000161	0.000779	CcSEcCtD
Mianserin—CYP1A2—Metabolism—TYMS—pancreatic cancer	8.33e-06	2.87e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	8.3e-06	2.87e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—SRC—pancreatic cancer	8.3e-06	2.86e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	8.29e-06	2.86e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CD44—pancreatic cancer	8.29e-06	2.86e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	8.26e-06	2.85e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—KRAS—pancreatic cancer	8.21e-06	2.83e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	8.18e-06	2.82e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	8.14e-06	2.81e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	8.13e-06	2.81e-05	CbGpPWpGaD
Mianserin—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	8.11e-06	2.8e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—KRAS—pancreatic cancer	8.09e-06	2.79e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—VEGFA—pancreatic cancer	8.08e-06	2.79e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—KRAS—pancreatic cancer	8.08e-06	2.79e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	8.08e-06	2.79e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	8.08e-06	2.79e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.06e-06	2.78e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	8.05e-06	2.78e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	8.04e-06	2.78e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	8.03e-06	2.77e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	8.03e-06	2.77e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	8.03e-06	2.77e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—STAT3—pancreatic cancer	8e-06	2.76e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	8e-06	2.76e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—APOE—pancreatic cancer	8e-06	2.76e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—MYC—pancreatic cancer	7.99e-06	2.76e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—NRAS—pancreatic cancer	7.99e-06	2.76e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	7.97e-06	2.75e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	7.97e-06	2.75e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	7.96e-06	2.75e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	7.95e-06	2.75e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GCG—pancreatic cancer	7.95e-06	2.74e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	7.93e-06	2.74e-05	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—AKT1—pancreatic cancer	7.92e-06	2.73e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	7.88e-06	2.72e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTGS2—pancreatic cancer	7.88e-06	2.72e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	7.85e-06	2.71e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	7.82e-06	2.7e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	7.82e-06	2.7e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	7.81e-06	2.69e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	7.8e-06	2.69e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	7.8e-06	2.69e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	7.78e-06	2.69e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	7.76e-06	2.68e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	7.74e-06	2.67e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	7.62e-06	2.63e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	7.61e-06	2.63e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	7.59e-06	2.62e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	7.57e-06	2.61e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	7.57e-06	2.61e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	7.55e-06	2.61e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—PIK3CA—pancreatic cancer	7.54e-06	2.6e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	7.49e-06	2.59e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	7.49e-06	2.59e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	7.48e-06	2.58e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—STK11—pancreatic cancer	7.47e-06	2.58e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	7.45e-06	2.57e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MYC—pancreatic cancer	7.44e-06	2.57e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	7.43e-06	2.57e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	7.43e-06	2.56e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	7.43e-06	2.56e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	7.42e-06	2.56e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	7.39e-06	2.55e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	7.38e-06	2.55e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	7.36e-06	2.54e-05	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	7.36e-06	2.54e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTEN—pancreatic cancer	7.33e-06	2.53e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	7.32e-06	2.53e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	7.3e-06	2.52e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—pancreatic cancer	7.3e-06	2.52e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CASP3—pancreatic cancer	7.29e-06	2.52e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—EGFR—pancreatic cancer	7.28e-06	2.51e-05	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	7.24e-06	2.5e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—SRC—pancreatic cancer	7.23e-06	2.5e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	7.23e-06	2.49e-05	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	7.22e-06	2.49e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	7.22e-06	2.49e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	7.21e-06	2.49e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—SRC—pancreatic cancer	7.2e-06	2.48e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—pancreatic cancer	7.19e-06	2.48e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—pancreatic cancer	7.18e-06	2.48e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	7.17e-06	2.48e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CASP3—pancreatic cancer	7.16e-06	2.47e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—pancreatic cancer	7.14e-06	2.46e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCND1—pancreatic cancer	7.1e-06	2.45e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	7.09e-06	2.45e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	7.05e-06	2.43e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	7.03e-06	2.43e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	7.01e-06	2.42e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	7e-06	2.42e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	6.98e-06	2.41e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—HRAS—pancreatic cancer	6.98e-06	2.41e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	6.98e-06	2.41e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCND1—pancreatic cancer	6.97e-06	2.4e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PPARG—pancreatic cancer	6.96e-06	2.4e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	6.96e-06	2.4e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	6.94e-06	2.4e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	6.92e-06	2.39e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	6.91e-06	2.39e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	6.9e-06	2.38e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MMP9—pancreatic cancer	6.89e-06	2.38e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—HRAS—pancreatic cancer	6.88e-06	2.37e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTEN—pancreatic cancer	6.87e-06	2.37e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—pancreatic cancer	6.87e-06	2.37e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—HRAS—pancreatic cancer	6.87e-06	2.37e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTEN—pancreatic cancer	6.85e-06	2.36e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	6.83e-06	2.36e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	6.82e-06	2.35e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	6.82e-06	2.35e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	6.79e-06	2.34e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	6.78e-06	2.34e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	6.77e-06	2.34e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—APOE—pancreatic cancer	6.77e-06	2.34e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MMP9—pancreatic cancer	6.76e-06	2.33e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	6.75e-06	2.33e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	6.74e-06	2.33e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	6.73e-06	2.32e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTEN—pancreatic cancer	6.72e-06	2.32e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	6.72e-06	2.32e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	6.7e-06	2.31e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	6.68e-06	2.31e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	6.59e-06	2.27e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	6.57e-06	2.27e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	6.57e-06	2.27e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—pancreatic cancer	6.56e-06	2.27e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	6.56e-06	2.26e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	6.53e-06	2.25e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MYC—pancreatic cancer	6.48e-06	2.24e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	6.47e-06	2.23e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MYC—pancreatic cancer	6.45e-06	2.23e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	6.43e-06	2.22e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—TYMS—pancreatic cancer	6.43e-06	2.22e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.41e-06	2.21e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	6.37e-06	2.2e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	6.35e-06	2.19e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—SRC—pancreatic cancer	6.35e-06	2.19e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	6.34e-06	2.19e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	6.34e-06	2.19e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	6.31e-06	2.18e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	6.31e-06	2.18e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	6.29e-06	2.17e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	6.28e-06	2.17e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	6.27e-06	2.17e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	6.26e-06	2.16e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—SRC—pancreatic cancer	6.25e-06	2.16e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—SRC—pancreatic cancer	6.24e-06	2.15e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	6.2e-06	2.14e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	6.19e-06	2.14e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	6.17e-06	2.13e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—AKT1—pancreatic cancer	6.16e-06	2.13e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	6.14e-06	2.12e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	6.13e-06	2.12e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—STAT3—pancreatic cancer	6.13e-06	2.11e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	6.11e-06	2.11e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NRAS—pancreatic cancer	6.11e-06	2.11e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—pancreatic cancer	6.11e-06	2.11e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	6.09e-06	2.1e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	6.07e-06	2.1e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—AKT1—pancreatic cancer	6.07e-06	2.1e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—AKT1—pancreatic cancer	6.07e-06	2.09e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	6.03e-06	2.08e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	6.03e-06	2.08e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—STAT3—pancreatic cancer	6.01e-06	2.08e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	6.01e-06	2.08e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NRAS—pancreatic cancer	6e-06	2.07e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	5.99e-06	2.07e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	5.98e-06	2.06e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	5.96e-06	2.06e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PPARG—pancreatic cancer	5.9e-06	2.04e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—HRAS—pancreatic cancer	5.84e-06	2.02e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	5.8e-06	2e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	5.7e-06	1.97e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MYC—pancreatic cancer	5.69e-06	1.96e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	5.69e-06	1.96e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	5.68e-06	1.96e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MYC—pancreatic cancer	5.6e-06	1.93e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MYC—pancreatic cancer	5.59e-06	1.93e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	5.59e-06	1.93e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	5.57e-06	1.92e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EGFR—pancreatic cancer	5.57e-06	1.92e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	5.54e-06	1.91e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	5.54e-06	1.91e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	5.53e-06	1.91e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	5.51e-06	1.9e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	5.5e-06	1.9e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	5.48e-06	1.89e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTGS2—pancreatic cancer	5.48e-06	1.89e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	5.48e-06	1.89e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	5.47e-06	1.89e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	5.47e-06	1.89e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EGFR—pancreatic cancer	5.47e-06	1.89e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	5.37e-06	1.85e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	5.32e-06	1.84e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—pancreatic cancer	5.32e-06	1.84e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—pancreatic cancer	5.3e-06	1.83e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	5.27e-06	1.82e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—pancreatic cancer	5.26e-06	1.82e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—APOE—pancreatic cancer	5.23e-06	1.8e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—AKT1—pancreatic cancer	5.2e-06	1.8e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	5.17e-06	1.79e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	5.17e-06	1.79e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—pancreatic cancer	5.16e-06	1.78e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—AKT1—pancreatic cancer	5.16e-06	1.78e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	5.15e-06	1.78e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	5.09e-06	1.76e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	5.09e-06	1.76e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	5.08e-06	1.75e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	5.06e-06	1.75e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	4.98e-06	1.72e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	4.93e-06	1.7e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	4.85e-06	1.67e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	4.83e-06	1.67e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTEN—pancreatic cancer	4.78e-06	1.65e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	4.75e-06	1.64e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	4.74e-06	1.64e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	4.72e-06	1.63e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	4.71e-06	1.62e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	4.68e-06	1.62e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—pancreatic cancer	4.67e-06	1.61e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	4.66e-06	1.61e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTGS2—pancreatic cancer	4.64e-06	1.6e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—pancreatic cancer	4.6e-06	1.59e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—pancreatic cancer	4.59e-06	1.58e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PPARG—pancreatic cancer	4.55e-06	1.57e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	4.5e-06	1.55e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	4.47e-06	1.54e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—HRAS—pancreatic cancer	4.47e-06	1.54e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	4.4e-06	1.52e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—HRAS—pancreatic cancer	4.39e-06	1.51e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	4.35e-06	1.5e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	4.33e-06	1.49e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—AKT1—pancreatic cancer	4.23e-06	1.46e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	4.18e-06	1.44e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	4.15e-06	1.43e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTEN—pancreatic cancer	4.05e-06	1.4e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	4e-06	1.38e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—AKT1—pancreatic cancer	3.96e-06	1.37e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—AKT1—pancreatic cancer	3.95e-06	1.36e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	3.88e-06	1.34e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—AKT1—pancreatic cancer	3.88e-06	1.34e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	3.61e-06	1.25e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS2—pancreatic cancer	3.58e-06	1.24e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	3.53e-06	1.22e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3.37e-06	1.16e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTEN—pancreatic cancer	3.12e-06	1.08e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.86e-06	9.86e-06	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.75e-06	9.5e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—AKT1—pancreatic cancer	2.33e-06	8.05e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	2.2e-06	7.61e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.8e-06	6.21e-06	CbGpPWpGaD
